Keryx Biopharmaceuticals Inc. (KERX)
Keryx Biopharmaceuticals is a commercial stage biopharmaceutical company focused on bringing medicines to people with kidney disease. Co.'s marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is used for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. Auryxia is also for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. Ferric citrate is also approved in Japan under the trade name Riona and marketed by Co.'s Japanese partner, Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd., and approved in Europe as Fexeric.
|
March 28, 2024 7:23 PM Eastern
Hold (2.50 out of 4)
100th percentile
|
|